S497
Clinical - Gynaecological
ESTRO 2026
Conclusion: Adjuvant EBRT provides effective pelvic control in endometrial cancer. Carcinosarcoma and ER-negative tumours significantly increased the risk of locoregional recurrence at 2 years. Most failures outside the radiotherapy field occur within 2 years. Isolated marginal and para-aortic recurrences were uncommon which would support only extending the radiotherapy field to include the common iliac and para-aortic regions in FIGO stage 3C1 and 3C2 disease,
respectively. References:
1.Karkia R, Nyakunengwa TR, Uwins C, et al. Endometrial Cancer: Analysing Patterns of Recurrence and Real-Life Outcome Data Using the 2020 ESGO-ESTRO-ESP Risk Stratification System. Clin Oncol (R Coll Radiol). 2024;36(11):719-727. doi:10.1016/j.clon.2024.06.0012.Zouridis A, Zarrindej K, Rencher J, et al. The Prognostic Characteristics and Recurrence Patterns of High Grade Endometrioid Endometrial Cancer: A Large Retrospective Analysis of a Tertiary Center. J Clin Med. 2023;12(9):3141. Published 2023 Apr 26. doi:10.3390/jcm12093141 Keywords: endometrial cancer, recurrence patterns
Made with FlippingBook - Share PDF online